Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have been given a consensus rating of "Buy" by the six ratings firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $34.50.

Several analysts recently issued reports on CAPR shares. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th.

Capricor Therapeutics Stock Down 4.9 %

Shares of NASDAQ CAPR traded down $0.46 during trading on Friday, reaching $8.94. The company had a trading volume of 303,879 shares, compared to its average volume of 1,449,652. The business's 50-day moving average is $12.95 and its 200 day moving average is $15.15. The stock has a market cap of $408.39 million, a PE ratio of -8.43 and a beta of 4.65. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. The business had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. On average, analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently made changes to their positions in the company. Summit Investment Advisors Inc. boosted its holdings in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at about $68,000. AlphaQuest LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter worth $78,000. Finally, New York State Common Retirement Fund lifted its position in Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.